ArticleRadiation oncology (London, England)2026
Definitive single-fraction ablative radiotherapy for early-stage breast cancer: DESERT-I trial - a dose-escalation study protocol.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06671691 (Phase I Dose-Escalation Clinical Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Patients with Low-risk Hormone Receptor-positive and Her2-negative Breast Cancer Not Suitable or Who Refuse Surgery), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Dose-Escalation Clinical Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Patients with Low-risk Hormone Receptor-positive and Her2-negative Breast Cancer Not Suitable or Who Refuse Surgery: DESERT I Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThere is a growing trend toward more tolerable and less aggressive treatments for breast cancer patients. For low-risk patients, accelerated partial breast irradiation (APBI) following conservative surgery is a widely used treatment. However, partly due to the development of modern techniques such as stereotactic ablative radiation therapy (SABR), the use of radiotherapy in breast cancer as a neoadjuvant approach has been gaining relevance in recent years. Given the promising results reported in several studies, the use of SABR as a definitive treatment for breast cancer warrants further investigation. The DESERT-I trial is a prospective dose-escalation study designed to evaluate 5 dose levels of definitive single-dose ablative radiotherapy in patients with early-stage breast cancer.
methodsEligible patients must have confirmed non-lobular invasive breast cancer that meets the following characteristics: unifocal, estrogen receptor-positive, HER2-negative, tumor size smaller than 3 cm and clinically negative axillary staging. The primary objective of the study is to determine the maximum tolerated dose by assessing dose-limiting toxicity across 5 cohorts: 20 Gy, 23 Gy, 26 Gy, 28 Gy, and 30 Gy. Secondary objectives include evaluating chronic toxicity, quality of life, cosmetic outcomes, pathological response (assessed via core biopsy at 6 and 12 months post-treatment), radiological response (evaluated through MRI or contrast-enhanced mammography at 12 months post-treatment), and analyzing biomarkers and tumor microenvironment in liquid biopsy and tumor tissue. DISCUSSION: The use of definitive radiotherapy in breast cancer remains a largely uncharted area. Currently, the optimal radiation dose required to achieve the best oncological outcome with acceptable toxicity is unknown. The DESERT-I clinical trial aims to determine the maximum tolerated dose across 5 different cohorts, with the goal of using this safe dose in a larger patient population in the phase II study. Additionally, the trial will analyze biomarkers and study tumor microenvironment using both liquid biopsy and tumor tissue. These findings could lay the groundwork for better patient selection and the future combination of SABR with immunotherapy.
trial registrationThis trial was registered on 4th November 2024 with ClinicalTrials.gov Identifier: NCT06671691.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.